I 
116TH CONGRESS 
2D SESSION 
H. R. 6282 
To establish a commission to assess, evaluate, and address the dependence 
of the United States on medications, devices, and medical equipment 
from foreign countries. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 13, 2020 
Mr. RUIZ (for himself, Ms. UNDERWOOD, and Mr. DAVID P. ROE of Ten-
nessee) introduced the following bill; which was referred to the Committee 
on Energy and Commerce 
A BILL 
To establish a commission to assess, evaluate, and address 
the dependence of the United States on medications, 
devices, and medical equipment from foreign countries. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Commission on Amer-
ica’s Medical Security Act’’. 
SEC. 2. NATIONAL ACADEMIES REPORT ON AMERICA’S 
MEDICAL SUPPLY SECURITY. 
(a) IN GENERAL.—Not later than 60 days after the 
date of enactment of this Act, the Secretary of Health and 
VerDate Sep 11 2014 
01:19 Mar 28, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6282.IH
H6282
pamtmann on DSKBC07HB2PROD with BILLS
Human Services shall enter into an agreement with the 
National Academies of Sciences, Engineering, and Medi-
cine (referred to in this section as the ‘‘National Acad-
emies’’) to examine, and, in a manner that does not com-
promise national security, report on, the security of the 
United States medical product supply chain. 
(b) PURPOSES.—The report developed under this sec-
tion shall— 
(1) assess and evaluate the dependence of the 
United States, including the private commercial sec-
tor, States, and the Federal Government, on critical 
drugs and devices that are sourced or manufactured 
outside of the United States, which may include an 
analysis of— 
(A) the supply chain of critical drugs and 
devices of greatest priority to providing health 
care; 
(B) any potential public health security or 
national security risks associated with reliance 
on critical drugs and devices sourced or manu-
factured outside of the United States, which 
may include previous or existing shortages and 
public health emergencies, such as infectious 
disease outbreaks, bioterror attacks, and other 
public health threats; 
VerDate Sep 11 2014 
01:19 Mar 28, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6282.IH
H6282
pamtmann on DSKBC07HB2PROD with BILLS
(C) any existing supply chain information 
gaps, as applicable; and 
(D) potential economic impact of increased 
domestic manufacturing; and 
(2) provide recommendations, which may in-
clude a plan to improve the resiliency of the supply 
chain for critical drugs and devices as described in 
paragraph 
(1), 
and 
to 
address 
any 
supply 
vulnerabilities or potential disruptions of such prod-
ucts that would significantly affect or pose a threat 
to public health security or national security, as ap-
propriate, which may include strategies to— 
(A) promote supply chain redundancy and 
contingency planning; 
(B) encourage domestic manufacturing, in-
cluding consideration of economic impacts, if 
any; 
(C) improve supply chain information 
gaps; 
(D) improve planning considerations for 
medical product supply chain capacity during 
public health emergencies; and 
(E) promote the accessibility of such drugs 
and devices. 
VerDate Sep 11 2014 
01:19 Mar 28, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6282.IH
H6282
pamtmann on DSKBC07HB2PROD with BILLS
(c) INPUT.—In conducting the study and developing 
the report under subsection (b), the National Academies 
shall— 
(1) consider input from the Department of 
Health and Human Services, the Department of 
Homeland Security, the Department of Defense, the 
Department of Commerce, the Department of State, 
the Department of Veterans Affairs, the Department 
of Justice, and any other Federal agencies as appro-
priate; and 
(2) consult with relevant stakeholders, which 
may include conducting public meetings and other 
forms of engagement, as appropriate, with health 
care providers, medical professional societies, State- 
based societies, public health experts, State and local 
public health departments, State medical boards, pa-
tient groups, medical product manufacturers, health 
care distributors, wholesalers and group purchasing 
organizations, pharmacists, and other entities with 
experience in health care and public health, as ap-
propriate. 
(d) DEFINITIONS.—In this section, the terms ‘‘de-
vice’’ and ‘‘drug’’ have the meanings given such terms in 
VerDate Sep 11 2014 
01:19 Mar 28, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6282.IH
H6282
pamtmann on DSKBC07HB2PROD with BILLS
section 201 of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 321). 
Æ 
VerDate Sep 11 2014 
01:19 Mar 28, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H6282.IH
H6282
pamtmann on DSKBC07HB2PROD with BILLS